PolyPid (PYPD) Expected to Release Earnings on Wednesday

PolyPid (NASDAQ:PYPD) is anticipated to issue its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect the company to post earnings of $0.46 per share and revenue of $30.00 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 11, 2026 at 8:30 AM ET.

PolyPid (NASDAQ:PYPD) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.35) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.03. On average, analysts expect PolyPid to post ($0.44) EPS for the current fiscal year and ($0.85) EPS for the next fiscal year.

PolyPid Trading Up 0.7%

PolyPid stock opened at $5.46 on Wednesday. PolyPid has a 1-year low of $3.50 and a 1-year high of $5.84. The firm has a market capitalization of $104.18 million, a price-to-earnings ratio of -3.69 and a beta of 1.43. The firm’s fifty day moving average price is $5.21 and its two-hundred day moving average price is $4.74.

Wall Street Analysts Forecast Growth

PYPD has been the topic of several recent research reports. Wall Street Zen raised shares of PolyPid from a “hold” rating to a “buy” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of PolyPid in a research report on Friday, September 18th. HC Wainwright reiterated a “buy” rating and set a $13.00 price target on shares of PolyPid in a report on Tuesday, July 21st. Oppenheimer initiated coverage on PolyPid in a research report on Tuesday, October 27th. They issued an “outperform” rating and a $10.00 price target for the company. Finally, Craig Hallum set a $12.00 price objective on PolyPid in a research note on Wednesday, July 22nd. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $11.00.

About PolyPid

PolyPid Ltd. (NASDAQ: PYPD) is a clinical-stage biopharmaceutical company focused on developing locally administered therapies designed to provide controlled and sustained drug release at treatment sites. The company’s technology is intended to maintain therapeutic drug concentrations over extended periods while limiting systemic exposure.

PolyPid’s lead product candidate is D-PLEX100, an investigational formulation based on doxycycline and the company’s proprietary PLEX polymeric matrix.